Bryan Johnson spends millions on his Blueprint longevity protocol. We break down his full supplement stack, the science behind each intervention, and what you can adopt on a budget.
Bryan Johnson is arguably the most prominent self-experimenter in longevity history. The PayPal/Braintree entrepreneur sold his company to PayPal for $800 million and redirected a substantial portion of his wealth toward a single goal: achieving the youngest possible biological age in every measurable organ system simultaneously. His "Blueprint" protocol is documented in painstaking detail on his website blueprint.bryanjohnson.com and in peer-reviewed publications, making it the most transparent extreme longevity programme in existence. The protocol reportedly costs approximately $2 million per year in its full form, including medical supervision, testing, and interventions.
Whether Johnson is an inspiration or a cautionary tale depends on whom you ask. Critics point out that the obsessiveness required by his protocol — a 21-item morning supplement regimen, a precisely calibrated 2,250 calorie diet consumed before 11am, and daily medical-grade testing — is incompatible with most people's lives and values. Supporters note that he is generating unprecedented individual-level longevity data and demonstrating that biological markers of aging can be systematically measured and improved. He reports that his biological age, as measured by multiple organ-specific tests, is significantly younger than his chronological age.
What is difficult to dispute is that his protocol is meticulously designed, medically supervised by Dr. Oliver Zolman, and grounded in existing science — even if the overall approach is extreme. This article covers his supplement stack as documented through 2025, grouped by biological function.
Acarbose (50 mg with meals): Acarbose is a diabetes drug that reduces post-meal blood glucose spikes by inhibiting alpha-glucosidase enzymes in the intestine, slowing carbohydrate digestion. Johnson takes it based on the Interventions Testing Program (ITP) data showing lifespan extension in male mice, and to reduce glucose-driven glycation damage. Glycation — the non-enzymatic attachment of glucose to proteins — is increasingly recognised as a driver of cellular aging and tissue stiffening.
Metformin ER (1,500-1,800 mg/day): Despite Attia's concerns about exercise interference, Johnson continues metformin as part of his glucose management strategy, arguing that his dietary approach and the specific biomarker data he tracks justify it in his specific context. Extended-release formulations reduce GI side effects.